Phathom Pharmaceuticals annual return on assets (roa)
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Return on Assets (ROA) Growth & History (PHAT)
Phathom Pharmaceuticals's return on assets (roa) was −69.41% for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −69.41% | +14.99 pp |
| 2024 | 2024-12-31 | −84.41% | −14.73 pp |
| 2023 | 2023-12-31 | −69.68% | +41.96 pp |
| 2022 | 2022-12-31 | −111.63% | −52.24 pp |
| 2021 | 2021-12-31 | −59.39% | −12.65 pp |
| 2020 | 2020-12-31 | −46.74% | +150.98 pp |
| 2019 | 2019-12-31 | −197.71% | — |
Phathom Pharmaceuticals quarterly return on assets (roa)
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −34.32% | +81.60 pp |
| Q1 2026 | 2026-03-31 | −52.49% | +53.79 pp |
| Q4 2025 | 2025-12-31 | −69.41% | +14.99 pp |
| Q3 2025 | 2025-09-30 | −87.53% | +21.26 pp |
| Q2 2025 | 2025-06-30 | −115.93% | −14.25 pp |
| Q1 2025 | 2025-03-31 | −106.28% | −7.73 pp |
| Q4 2024 | 2024-12-31 | −84.41% | −14.73 pp |
| Q3 2024 | 2024-09-30 | −108.79% | −28.11 pp |
| Q2 2024 | 2024-06-30 | −101.68% | −24.39 pp |
| Q1 2024 | 2024-03-31 | −98.55% | +34.44 pp |
| Q4 2023 | 2023-12-31 | −69.68% | +41.96 pp |
| Q3 2023 | 2023-09-30 | −80.68% | +2.28 pp |
| Q2 2023 | 2023-06-30 | −77.28% | −0.63 pp |
| Q1 2023 | 2023-03-31 | −132.99% | −57.27 pp |
| Q4 2022 | 2022-12-31 | −111.63% | −52.24 pp |
| Q3 2022 | 2022-09-30 | −82.96% | −12.51 pp |
| Q2 2022 | 2022-06-30 | −76.66% | −8.47 pp |
| Q1 2022 | 2022-03-31 | −75.72% | −19.37 pp |
| Q4 2021 | 2021-12-31 | −59.39% | −12.65 pp |
| Q3 2021 | 2021-09-30 | −70.45% | +41.18 pp |
| Q2 2021 | 2021-06-30 | −68.19% | +95.52 pp |
| Q1 2021 | 2021-03-31 | −56.35% | — |
| Q4 2020 | 2020-12-31 | −46.74% | — |
| Q3 2020 | 2020-09-30 | −111.63% | — |
| Q2 2020 | 2020-06-30 | −163.71% | — |
Phathom Pharmaceuticals return on assets (roa) trends
Over the last five fiscal years, Phathom Pharmaceuticals's return on assets (roa) decreased from −46.74% to −69.41%, a change of −22.68 percentage points. The latest reported quarter, Q2 2026, shows −34.32%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
